Breathing new life into inhaled medicines

Taking an inhaled medication can be as easy as taking a breath. This simple and painless drug-delivery method has always been a preferred option for respiratory drugs. The inhaled medicine market is booming. There are more than 100 pharmaceutical compounds in development for the treatment of respiratory ailments, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). It is also quickly becoming the method of choice for a variety of more diverse and systemic therapies as an alternative to needle injections or other invasive applications, which are less desirable to patients—such as for Parkinson’s disease, seizures, diabetes and analgesics.

Navigating the genetic complexity of autism spectrum disorder (ASD) with insights from Labcorp's Reveal® SNP Microarray Pediatric Test

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder typically characterized by deficits in social behaviors and communication skills emerging within the first three years of life. Given ASD’s spectrum nature and the absence of clear biomarkers or diagnostic measures, it’s important to understand ASD’s genetic origins.

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C. , April 29, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its

Labcorp Announces 2024 First Quarter Results

Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2.69 versus $2.34 Adjusted EPS: $3.68 versus $3.46 Full-Year 2024 Guidance: Raised midpoint and

Labcorp Announces Winning Bid for Select Assets of Invitae

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C. , April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and

Spatial transcriptomic study of the tumor microenvironment in HNSCC

Enhanced Detection of ctDNA Molecular Response for Immunotherapy Treated Non-small Cell Lung Cancer Through Analyses of Cell-free and Matched White Blood Cell DNA